Nevanac (nepafenac) / Novartis, Harrow Health - LARVOL DELTA

Unilateral facial dermatitis induced by topical nepafenac mimicking infectious folliculitis (EADV 2026) - No abstract available

Dermatitis • Dermatology • Immunology

Comparison of common pharmacological strategies for post-photorefractive keratectomy pain management: a systematic review and network meta-analysis. (PubMed, Front Med (Lausanne)) - "Regarding safety, Diclofenac (SUCRA = 0.81), Ketorolac (0.70), and Nepafenac (0.53) demonstrated the optimal profiles. The highest numbers of adverse events occurred with Pregabalin (39 cases), Fentanyl (20 cases), and Codeine combined with Acetaminophen (13 cases); however, safety conclusions remain limited as only seven studies reported highly heterogeneous adverse event data...Clinicians should synthesize these comparative findings with individual patient profiles to optimize drug selection, ensuring a balanced approach between effective pain relief and minimized adverse risks. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251238092, CRD420251238092."

Journal • Retrospective data • Review • Pain

Comparison Between Low-Dose and High-Dose Nepafenac Sodium (clinicaltrials.gov) - P=N/A | N=176 | Completed | Sponsor: Muhammad Aamir Latif

New trial • Cataract • Macular Edema • Ophthalmology

NEPERM: Perioperative Topical Nepafenac After Epiretinal Membrane Surgery (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: Ankara Yildirim Beyaz?t University

New P4 trial • Retinal Disorders

Choroidal vascularity and thickness modulation with topical nepafenac after phacoemulsification: a comparative study in diabetic and non-diabetic eyes. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "Topical nepafenac significantly reduces postoperative increases in CVI-particularly in diabetic patients-suggesting a protective effect against inflammation-associated choroidal vascular alterations. Nepafenac may help preserve choroidal vascular integrity after cataract surgery, highlighting its value as an adjunctive anti-inflammatory therapy, especially for diabetic individuals at higher inflammatory risk."

Journal • Cataract • Diabetic Macular Edema • Inflammation • Metabolic Disorders • Ophthalmology

Bromfenac versus nepafenac for pain management following transepithelial photorefractive keratectomy. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "Both Nepafenac and Bromfenac significantly reduced postoperative pain following t-PRK compared to systemic analgesia. These findings support the use of topical NSAIDs in optimizing post-PRK pain management."

Journal • Pain

Efficacy of Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Cystoid Macular Edema Following Cataract Phacoemulsification (clinicaltrials.gov) - P4 | N=88 | Completed | Sponsor: Pomeranian Medical University Szczecin

New P4 trial • Cataract • Macular Edema • Ophthalmology

Comparison of topical nepafenac 0.1% and 0.3% for the treatment of pseudophakic cystoid macular edema following cataract surgery. (PubMed, BMC Ophthalmol) - "Topical nepafenac 0.1% and 0.3% were both associated with improvement in PCME. Group-1 showed better early anatomical and later visual outcomes, whereas Group-2 showed a greater early CVI increase. However, these findings do not establish the superiority of either regimen."

Journal • Cataract • Macular Edema • Ophthalmology

Fabrication of Fe-Mn mixed oxide nanosheets via microwave assistance as an advanced probe for ultra-sensitive nepafenac sensing in diverse matrices; paving the way for future applications. (PubMed, BMC Chem) - "Additionally, the environmental sustainability of the approach was critically assessed using multiple contemporary greenness evaluation tools (ComplexMoGAPI, AGREE, AGSA and BAGI), confirming its alignment with green analytical chemistry principles. This study demonstrates the synergistic benefits of microwave-assisted synthesis and rational nano-catalyst design, offering a promising platform for future applications in pharmaceutical analysis and clinical diagnostics."

Journal • CNS Disorders • Psychiatry

Evaluating the Efficacy of Topical NSAIDs in Alleviating Corneal Clouding in Pediatric CHED: A Clinical and Genomic Appraisal (ARVO 2026) - "Understanding these challenges, we conducted the first ever prospective, randomised control trial exploring the role of topical Nepafenac eye drops in improving the corneal cloudiness in CHED cohort...Even in children with known genetic changes causing CHED, the drops didn't help. Although lab tests once showed promise, this real-world trial found no benefit, suggesting future treatments need new approaches, better drug delivery, or additional therapies to help these children."

Clinical • Ophthalmology • SLC4A1

Topical Triple Therapy in Small Idiopathic Macular Holes <300 µm: A Retrospective Matched-Cohort Analysis (ARVO 2026) - "Conclusions Topical therapy with dorzolamide, nepafenac, and prednisolone did not demonstrate a statistically significant advantage in anatomical closure rate compared with the untreated cohort in small idiopathic full-thickness macular holes <300 µm. The favorable closure outcomes reported in earlier retrospective studies were not reproducible in this patient population."

Retrospective data • Ophthalmology • Retinal Disorders

Effects of Topical Steroids and Non-Steroidal Anti-Inflammatory Drugs on Gastrointestinal Bleeding in Rats. (PubMed, Vet Med Sci) - "Short-term topical ocular steroid and NSAID treatments were not associated with statistically significant systemic gastrointestinal alterations under the conditions of this study."

Journal • Preclinical • Gastroenterology

Effect of Topical NSAIDs (Diclofenac 0.1%, Nepafenac 0.1%, Nepafenac 0.3%) on Pain Management During Intravitreal Injections: A Prospective, Non-Randomized, Case-Control Trial (ChiCTR) - P=N/A | N=400 | Completed | Sponsor: Fauji Foundation Hospital; Fauji Foundation Hospital | Not yet recruiting ➔ Completed

Trial completion • Pain

Imaging cystoid macular oedema secondary to branch retinal vein occlusion with spectral domain optical coherence tomography: A case report. (PubMed, SAGE Open Med Case Rep) - "The patient received an intravitreal injection of ranibizumab along with an adjunctive course of topical nepafenac (a nonsteroidal anti-inflammatory drug). A small intraretinal cyst close to the fovea, hard exudates, and progressing posterior vitreous detachment were, however, seen. This case underscores the significance of systemic metabolic dysfunction, the prognostic utility of optical coherence tomography biomarkers, and the necessity of therapeutic strategies in the management of branch retinal vein occlusion."

Journal • Diabetes • Macular Edema • Metabolic Disorders • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Type 2 Diabetes Mellitus

Progressive Intramembranous Cystic Changes in Macular Hole-Associated Epiretinal Proliferation Over 3 Years. (PubMed, J Vitreoretin Dis) - "On examination, MH-associated epiretinal proliferation was noted in the left eye, demonstrating increased thickness and cystic changes compared with the previous visit, for which topical nepafenac eye drops were advised... This report documents progressive structural changes in this infrequently encountered entity and explores the possible pathologic mechanisms through a review of relevant literature. Cystic changes with epiretinal proliferation may represent a benign process attributable to chronicity and often may not require intervention."

Journal • Cardiovascular • Diabetic Retinopathy • Glaucoma • Macular Edema • Ophthalmology • Retinal Disorders

#0525NEDEF: Effect of nepafenac/dexamethasone fixed dose combination vs. its individual components (nepafenac and dexamethasone monotherapies) on postoperative inflammation after cataract surgery: a randomized, multicentre, blinded-assessor, parallel-group clinical study NE.DE.F. STUDY (clinicaltrialsregister.eu) - P2/3 | N=432 | Not yet recruiting | Sponsor: Medivis S.r.l.

New P2/3 trial • Cataract • Inflammation • Ophthalmology

CAENLVLTELPMA: A Comparative Analysis of the Effectiveness of Nepafenac Combined With a Lubricant Versus a Lubricant Alone in the Treatment of Epiphora Associated With Lacrimal Punctum Stenosis (clinicaltrials.gov) - P4 | N=68 | Active, not recruiting | Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana

New P4 trial • Ophthalmology

Efficacy of Topical Nepafenac Versus Nepafenac With Perioperative Cyclopentolate for Pain Management After Photorefractive Keratectomy: A Comparative Clinical Evaluation. (PubMed, J Refract Surg) - "Contrary to theoretical expectations, adding cyclopentolate to nepafenac therapy worsened postoperative pain outcomes after PRK. For optimal pain management, a regimen of nepafenac alone appears superior to the combination therapy approach."

Clinical • Journal • Retrospective data • CNS Disorders • Pain • Sleep Disorder

Novel stable micellar formulation for ocular delivery of nepafenac: optimization, characterization and in-vitro evaluation. (PubMed, Drug Dev Ind Pharm) - "The optimized formulation demonstrated in-vitro safety as confirmed by MTT cell viability and HET-CAM ocular irritation assays, and exhibited physicochemical stability for up to 6 months under real-time storage conditions. The optimized micelle formulation can serve as a better alternative for ophthalmic delivery of nepafenac."

Journal • Preclinical • Ocular Inflammation • Ophthalmology • Uveitis

Transient maculopathy after intracameral injection of cefuroxime (PubMed, Ophthalmologie) - "These findings completely resolved within 6 days of treatment with prednisolone acetate and nepafenac eye drops, resulting in full visual recovery.Intracameral administration of antibiotics, in Europe as cefuroxime 1 mg/0.1 ml, is recommended for endophthalmitis prophylaxis at the end of cataract surgery. Patients who have undergone pars plana or anterior vitrectomy apparently have an inherently higher risk of developing maculopathy. Transient cefuroxime maculopathy usually has a benign, self-limiting course. Cataract surgeons should be aware of this condition and avoid overdosing that otherwise safe and effective drug."

Journal • Cataract • Macular Degeneration • Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders

Effect of Topical NSAIDs (Diclofenac 0.1%, Nepafenac 0.1%, Nepafenac 0.3%) on Pain Management During Intravitreal Injections: A Prospective, Non-Randomized, Case-Control Trial (ChiCTR) - P=N/A | N=400 | Not yet recruiting | Sponsor: Fauji Foundation Hospital Rawalpindi, Pakistan; Fauji Foundation Hospital

New trial • Pain

The effects of topical nepafenac on pupillary dynamics in early postoperative period following uneventful cataract surgery: a prospective randomized study. (PubMed, Int Ophthalmol) - "Adjunctive topical Nepafenac 0.1% use might attenuate early postoperative scotopic and mesopic pupil constriction following an uneventful cataract surgery. Although the effect appears most pronounced during the first postoperative week, this short-term benefit may be clinically relevant, particularly for patients with premium intraocular lens or those who rely heavily on low-light vision."

Clinical • Journal • Cataract • Inflammation • Ophthalmology

Analgesic efficacy of 7 different topical NSAIDs in panretinal photocoagulation-associated pain. (PubMed, BMC Ophthalmol) - "Bromfenac and indomethacin demonstrate consistent analgesic efficacy in nearly all patients with panretinal photocoagulation-related pain, while nepafenac 0.3% and diclofenac are effective in a majority of cases. However, heightened panretinal photocoagulation-related pain in females, patients aged ≤ 60 years and those with proliferative diabetic retinopathy may necessitate careful consideration in these populations."

Journal • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Pain • Retinal Disorders

Efficacy of Topical Non-Selective and COX-2 Selective NSAIDs in Accelerating Resolution of Acute Central Serous Chorioretinopathy: A Retrospective Analysis. (PubMed, Clin Ophthalmol) - "Patients received either topical ketorolac (n = 26, nonselective NSAID, four times daily) or observation alone (n = 63). Historical data (2007-2013) (n = 111) comparing COX-2 selective NSAIDs (bromfenac or nepafenac, n = 38) with observation (n = 73) were analyzed for comparison...The earlier recovery of normal vision and anatomical resolution may benefit patients clinically by reducing morbidity associated with prolonged retinal detachment. Prospective studies are warranted to confirm these findings and refine treatment protocols for acute CSCR."

Journal • Retrospective data • Ocular Inflammation • Ophthalmology • Retinal Disorders

Development of 3D printed biodegradable polymer-based drug delivery implants for post cataract surgery treatment. (PubMed, J Biomater Sci Polym Ed) - "The implant was designed to be placed into the capsular bag of the eye during the surgery and employs Poly(lactic-co-glycolic acid) (PLGA) as a drug carrier, delivering a combination of drugs such as Dexamethasone (DEX), Moxifloxacin (MOX), and Nepafenac (NEPA) directly into the eye...This approach demonstrates the feasibility of combining cataract surgery with post-operative drug delivery in a single procedure. The implants provided sustained drug release profiles consistent with clinical dosing regimens and were well substantiated in in vivo rabbit model, supporting their potential to improve patient compliance and recovery in future therapeutic applications."

Journal • Cataract • Ophthalmology